Literature DB >> 12436486

Correlation between HHV-6 reactivation and multiple sclerosis disease activity.

Svetlana Chapenko1, Andrejs Millers, Zaiga Nora, Inara Logina, Rita Kukaine, Modra Murovska.   

Abstract

This study examined the association between HHV-6 infection and multiple sclerosis (MS) and the relationship between HHV-6 reactivation and disease activity. The frequency of HHV-6 genomic sequences in peripheral blood mononuclear cells (PBMCs), the incidence of plasma viremia (nPCR), the transcription of viral mRNA in PBMCs (RT-PCR), the presence of antiviral IgM and IgG class antibodies in the plasma (IFA) of 16 relapsing/remitting and secondary progressive MS patients were studied in comparison with clinical manifestations of the disease, magnetic resonance imaging (MRI) of brain, and serum interleukin (IL)-12 concentrations (ELISA). The prevalence of HHV-6 infection was significantly higher in patients with MS (16/26) than in patients with other neurological diseases (6/21) and in blood donors (43/150). HHV-6 reactivation was found during periods of disease activity with Gadolinium-enhancing lesions on MRI in both relapsing/remitting and secondary progressive MS (10/13; 76.9%). In patients with active MS disease, serum concentrations of IL-12 were significantly higher in those patients with active HHV-6 infection than in patients with latent infection. The data confirm an association between HHV-6 infection and MS and show a correlation between HHV-6 reactivation and disease activity in relapsing/remitting and secondary progressive MS. The risk of an exacerbation of MS was significantly higher (P < 0.005) in patients with active HHV-6 infection than in patients with latent infection. A clear correlation between HHV-6 reactivation and serum IL-12 concentrations during disease activity has been demonstrated. The results suggest that HHV-6 reactivation is implicated in exacerbation of MS, possibly through modulation of IL-12 synthesis. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12436486     DOI: 10.1002/jmv.10258

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  37 in total

Review 1.  Human herpesvirus 6 infection as a trigger of multiple sclerosis.

Authors:  Konstantine I Voumvourakis; Dimitrios K Kitsos; Sotirios Tsiodras; George Petrikkos; Eleftherios Stamboulis
Journal:  Mayo Clin Proc       Date:  2010-10-06       Impact factor: 7.616

Review 2.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response.

Authors:  Tobias Derfuss; Reinhard Hohlfeld; Edgar Meinl
Journal:  J Neurol       Date:  2005-03-21       Impact factor: 4.849

4.  Detection frequency of human herpesviruses-6A, -6B, and -7 genomic sequences in central nervous system DNA samples from post-mortem individuals with unspecified encephalopathy.

Authors:  Svetlana Chapenko; Silvija Roga; Sandra Skuja; Santa Rasa; Maksims Cistjakovs; Simons Svirskis; Zane Zaserska; Valerija Groma; Modra Murovska
Journal:  J Neurovirol       Date:  2016-01-04       Impact factor: 2.643

5.  A Murine Herpesvirus Closely Related to Ubiquitous Human Herpesviruses Causes T-Cell Depletion.

Authors:  Swapneel J Patel; Guoyan Zhao; Vinay R Penna; Eugene Park; Elvin J Lauron; Ian B Harvey; Wandy L Beatty; Beatrice Plougastel-Douglas; Jennifer Poursine-Laurent; Daved H Fremont; David Wang; Wayne M Yokoyama
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

6.  Human herpesvirus 6A infection in CD46 transgenic mice: viral persistence in the brain and increased production of proinflammatory chemokines via Toll-like receptor 9.

Authors:  Joséphine M Reynaud; Jean-François Jégou; Jérémy C Welsch; Branka Horvat
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

7.  Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patients.

Authors:  Marta Garcia-Montojo; Virginia De Las Heras; Manuel Bartolome; Rafael Arroyo; Roberto Alvarez-Lafuente
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

8.  Human herpesvirus 6A (HHV-6A) and HHV-6B alter E2F1/Rb pathways and E2F1 localization and cause cell cycle arrest in infected T cells.

Authors:  Guy Mlechkovich; Niza Frenkel
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

Review 9.  Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation.

Authors:  Anthony L Komaroff; Philip E Pellett; Steven Jacobson
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

10.  CD8+ T Cells Prevent Lethality from Neonatal Murine Roseolovirus Infection.

Authors:  Swapneel J Patel; Wayne M Yokoyama
Journal:  J Immunol       Date:  2017-10-02       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.